Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells [mCRC]

ABSTRACT: Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells [mCRC]

PROVIDER: PRJNA823037 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18600445_1.fastq.gz	Fastqsanger.gz
	SRR18600445_2.fastq.gz	Fastqsanger.gz
	SRR18600446_1.fastq.gz	Fastqsanger.gz
	SRR18600446_2.fastq.gz	Fastqsanger.gz
	SRR18600447_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 84

Similar Datasets

Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells

Project description:Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells

| PRJNA823035 | ENA

Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells [NanoString]

Project description:Colorectal tumors are often densely infiltrated by immune cells that have a role in surveillance and modulation of tumor progression but are burdened by exhaustion mechanisms fueled by the tumor microenvironment, which must be counteracted to achieve control. Here, we deployed a multidimensional approach to unravel the T cell functional landscape in tumor and peritumoral tissues from primary colorectal cancers and liver metastases. We found that T-cells are mainly localized at the front edge and that tumor-infiltrating T cells co-express multiple inhibitory receptors and highlighted CD39 as the major driver of exhaustion in both primary and metastatic colorectal tumors. By CRISPR/Cas9 genome editing tools, we simultaneously redirected T-cell specificity employing a novel T-cell receptor targeting the HER-2 antigen, and disrupted CD39, thus generating triple-knockout engineered lymphocytes. We showed that the absence of CD39 confers HER2-specific T cells a functional advantage in eliminating HER2+ patient-derived organoids, starring the relevance of the CD39 axis for further exploitation in adoptive T-cell therapy strategies to treat primary and metastatic colorectal cancer.

2023-07-12 | GSE200131 | GEO

Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells [CRC]

2023-07-12 | GSE200130 | GEO

Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells [mCRC]

2023-07-12 | GSE200129 | GEO

Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells [CRC]

Project description:Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells [CRC]

| PRJNA823036 | ENA

Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells [NanoString]

Project description:Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells [NanoString]

| PRJNA823039 | ENA

Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-07-12 | GSE200133 | GEO

RNA-Seq of FACS-sorted, KIR-CD39-,KIR+CD39- and KIR+CD39+, Uterine NK cells (uNK cells) from human decidual samples

Project description:Uterine NK cells (uNK cells) form a distinct immune cell population in the endometrium and decidua. Here, we FACS-sorted KIR-CD39-,KIR+CD39- and KIR+CD39+ uNK cells from decidual samples.

2021-02-19 | E-MTAB-8709 | biostudies-arrayexpress

Comparison of human CD39- and CD39+ thymus-derived regulatory T-cells

Project description:CD39- and CD39+ human thymus-derived regulatory T-cells (tTreg) present as distinct subsets with specific functional and metabolic response patterns. Both cell types express equal levels of the canonical tTreg transcription factors FOXP3 and Helios and overexpression studies have shown that CD39 expression is independent of these two transcription factors. So far, no transcriptomic analyses to adress these differences have been performed. We used microarrays to detail the global programme of gene expression between CD39- and CD39+ human tTreg and identified distinct classes of up-regulated and down-regulated genes between these two subsets.

2020-07-02 | GSE131743 | GEO

A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer

Project description:HLA ligandome analysis of colorectal adenocarcinoma tissues obtained from liver metastases (mCRC) as well as adjacent non-malignant liver tissues was performed to characterize the natural HLA class I and class II presented ligands on both mCRC and adjacent liver tissue.

2019-12-11 | PXD015947 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data